MK-4827 (Niraparib): Selective PARP-1/-2 Inhibitor for BRCA-Mutant Cancer Research

Executive Summary: MK-4827 (Niraparib) is a selective small molecule inhibitor of PARP-1 and PARP-2 with sub-nanomolar potency (IC₅₀: 3.8 nM for PARP-1, 2.1 nM for PARP-2), enabling targeted inhibition of DNA repair in preclinical cancer models [APExBIO, A3617]. This compound exploits synthetic lethality in BRCA-1/2-deficient tumors—demonstrating CC₅₀ values of 10–100 nM in mutant cell lines while sparing healthy cells at micromolar concentrations. MK-4827 enhances radiotherapy efficacy in vivo, showing robust tumor suppression and minimal toxicity in xenograft models [Mei et al., 2025]. Its oral bioavailability, solubility profile (≥32 mg/mL in DMSO, ≥50.9 mg/mL in ethanol), and well-defined storage conditions make it a preferred PARP inhibitor for translational oncology workflows. This article clarifies mechanistic, benchmark, and workflow aspects, updating strategic guidance for researchers beyond existing summaries [see prior review].

Biological Rationale

Poly(ADP-ribose) polymerase (PARP) enzymes, primarily PARP-1 and PARP-2, are critical mediators of DNA single-strand break repair via poly(ADP-ribosyl)ation. Inhibition of PARP catalytic activity leads to accumulation of unrepaired single-strand breaks, which convert into double-strand breaks during DNA replication. Tumors with homologous recombination deficiency (HRD), notably those deficient in BRCA-1 or BRCA-2, are unable to efficiently repair these double-strand breaks, resulting in synthetic lethality and selective tumor cell death (Mei et al., 2025). This molecular rationale underpins the selective vulnerability of BRCA-mutant cancers to PARP inhibitors like MK-4827.

Mechanism of Action of MK-4827 (Niraparib), a Potent and Selective PARP-1/-2 Inhibitor

MK-4827 (Niraparib) is a competitive inhibitor that targets the NAD⁺-binding catalytic domains of PARP-1 and PARP-2. By binding to these sites (IC₅₀: 3.8 nM for PARP-1; 2.1 nM for PARP-2), MK-4827 prevents PARP-mediated transfer of ADP-ribose units to target proteins, thus blocking DNA repair signaling [APExBIO]. This inhibition causes persistent DNA single-strand breaks. During replication, these breaks evolve into double-strand breaks, especially cytotoxic in cells lacking BRCA-mediated homologous recombination. The result is selective apoptosis of BRCA-1/2 mutant tumor cells, sparing normal tissues with intact DNA repair machinery [detailed mechanism review].

Evidence & Benchmarks

• MK-4827 exhibits potent inhibition of recombinant PARP-1 (IC₅₀: 3.8 nM) and PARP-2 (IC₅₀: 2.1 nM) in biochemical assays (APExBIO).
• In BRCA-1 or BRCA-2 mutant cancer cell lines, MK-4827 demonstrates antiproliferative activity with CC₅₀ values of 10–100 nM under standard culture conditions (RPMI 1640, 10% FBS, 37°C, 5% CO₂) (3xflag.com).
• Normal human prostate and mammary epithelial cells show resistance at concentrations up to 10 μM, indicating tumor selectivity (APExBIO).
• In vivo, MK-4827 suppresses tumor growth in BRCA-1 mutant MDA-MB-436 breast cancer and p53-variable lung cancer xenografts, with significant extension of survival and minimal toxicity at oral doses (dose and schedule: 50 mg/kg, daily, 21 days) (Mei et al., 2025).
• Combination of MK-4827 with hyperthermia further sensitizes BRCA2-proficient ovarian cancer xenografts by downregulating BRCA2 expression and impairing RAD51 foci formation (Mei et al., 2025).
• MK-4827 acts as an effective radiosensitizer, enhancing the efficacy of ionizing radiation in preclinical tumor models (nsc23766.com).

Applications, Limits & Misconceptions

MK-4827 is widely adopted in preclinical research investigating DNA repair pathways, synthetic lethality, and the development of targeted therapies for BRCA-mutant and HR-deficient cancers. Key applications include:

• Establishing in vitro models of PARP inhibitor sensitivity and resistance in breast, ovarian, and lung cancers.
• Evaluating combination therapies, such as PARP inhibitors with hyperthermia or radiotherapy, to overcome intrinsic resistance in BRCA-proficient tumors [strategic guidance update].
• Validating DNA damage response biomarkers and mechanisms of acquired resistance, especially in translational workflows [roadmap extension].

Common Pitfalls or Misconceptions

• MK-4827 is not effective against tumors with intact BRCA-1/2 and functional homologous recombination; resistance is common in these settings (Mei et al., 2025).
• It should not be used in aqueous buffers; MK-4827 is insoluble in water and should be dissolved in DMSO or ethanol for biological assays (APExBIO).
• Long-term storage of prepared solutions is not recommended; stability is optimal at –20°C as dry compound (APExBIO).
• Results from cell line studies may not directly extrapolate to clinical efficacy due to tumor heterogeneity and microenvironmental effects.
• MK-4827 (Niraparib) is a research-use-only compound from APExBIO and is not intended for human or veterinary therapeutic applications.

Workflow Integration & Parameters

MK-4827 is supplied as a dry powder (MW: 320.39, C₁₉H₂₀N₄O) and should be reconstituted in DMSO (≥32 mg/mL) or ethanol (≥50.9 mg/mL with gentle warming). For cell-based assays, recommended working concentrations range from 10 nM to 10 μM depending on cell line sensitivity. For in vivo studies, oral dosing regimens (e.g., 50 mg/kg/day) have demonstrated efficacy in mouse xenograft models. Store at –20°C, protected from light and moisture. Avoid repeated freeze-thaw cycles and long-term solution storage.

For detailed use parameters and product availability, see the MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor product page from APExBIO.

Conclusion & Outlook

MK-4827 (Niraparib) remains a gold-standard tool for dissecting PARP-mediated DNA repair and developing targeted therapies against BRCA-mutant and HR-deficient cancers. Its robust potency, selectivity, and translational relevance have enabled advances in synthetic lethality, radiosensitization, and resistance modulation. Recent evidence now highlights the promise of combination approaches—such as hyperthermia-mediated BRCA2 reduction—to extend PARP inhibitor sensitivity even to BRCA2-proficient tumors (Mei et al., 2025). For comprehensive experimental design and strategic insights, this article updates and contextualizes prior reviews [see expanded workflow guidance].